Adaptive Biotechnologies Stock Price, News & Analysis

Adaptive Biotechnologies reported financial results for Q2 2021, showcasing 83% revenue growth year-over-year, reaching $38.5 million. Sequencing revenue grew by 132% to $18.6 million, while development revenue rose 53% to $20 million. Despite this growth, the company faced an operating loss of $49.3 million, worsening from $33.5 million in Q2 2020. The company has $689.5 million in cash and expects to generate $148 million to $155 million in revenue for the full year 2021, indicating 54% growth at the midpoint.

Adaptive Biotechnologies (Nasdaq: ADPT) will release its financial results for Q2 2021 after market close on August 4, 2021. A conference call with management will follow at 1:30 PM PT/4:30 PM ET, accessible via their website. The company focuses on decoding the adaptive immune system to develop diagnostics and treatments for diseases, including cancer and autoimmune conditions. They boast three commercial products and a comprehensive clinical pipeline aimed at personalized immune-driven therapies.

Adaptive Biotechnologies announces the use of its immunoSEQ T-MAP COVID technology in a Nature study demonstrating T-cell immune response to the Johnson & Johnson COVID-19 vaccine against variants like B.1.351. The findings suggest preserved T-cell responses, even as neutralizing antibodies wane, indicating T-cells may offer essential protection from variants. The research underscores the importance of measuring T-cell responses in vaccine trials, especially against emerging strains.

Adaptive Biotechnologies (Nasdaq: ADPT) is set to present over 20 abstracts focusing on its clonoSEQ® Assay for assessing minimal residual disease (MRD) in blood cancers at the upcoming ASCO and EHA meetings. The clonoSEQ Assay is the first FDA-cleared test for MRD in chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and B-cell acute lymphoblastic leukemia (B-ALL). The results emphasize its clinical relevance, particularly in monitoring treatment response and potential relapses.

Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in two upcoming investor conferences. The company will engage in a fireside chat at the William Blair 41st Annual Growth Stock Conference on June 1st at 6:40 a.m. PT and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8th at 12:50 p.m. PT. Interested parties can access the live and archived webcasts via the company’s website. Adaptive Biotechnologies focuses on translating the adaptive immune system's genetics into clinical products for disease diagnosis and treatment.

Adaptive Biotechnologies (ADPT) reported strong financial results for Q1 2021, with revenue of $38.4 million, marking an 84% year-over-year increase. The growth was driven by a 60% increase in sequencing revenue and a 103% increase in development revenue. However, operating expenses rose to $79.7 million, leading to a net loss of $40.6 million, compared to a loss of $31.4 million in Q1 2020. The company anticipates full-year 2021 revenue between $145 million and $155 million, indicating 52% growth at the midpoint.

Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in the BofA Securities 2021 Virtual Healthcare Conference. Management will engage in a fireside chat on May 11 at 8:45 a.m. PT. Interested parties can access the live and archived webcast on the company’s website. Adaptive Biotechnologies focuses on the adaptive immune system, developing diagnostic and therapeutic products for diseases like cancer and autoimmune conditions. The company has three commercial products and a strong clinical pipeline aimed at personalized medicine.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) plans to report its Q1 2021 financial results on May 5, 2021, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, available via webcast. The company leverages the adaptive immune system for disease diagnostics and treatments, boasting three commercial products and a promising clinical pipeline targeting conditions like cancer and autoimmune diseases. The results announcement and the conference call are critical for investors seeking insights into company performance and future growth.

Adaptive Biotechnologies (Nasdaq: ADPT) announced FDA Emergency Use Authorization for its T-Detect COVID test, the first T cell-based diagnostic for detecting prior SARS-CoV-2 infections. The test demonstrated 97.1% sensitivity and 100% specificity. Developed in collaboration with Microsoft, T-Detect COVID allows individuals uncertain about past infections to confirm their status, marking a significant milestone in diagnostic testing. This technology leverages T cells' capabilities for improved disease detection and is expected to pave the way for future diagnostic tests across various diseases.